The constitutive overexpression of Mer tyrosine kinase (MerTK), strongly associated with tumorigenesis and progression across multiple malignancies, establishes it as a promising therapeutic target for oncology discovery. In this study, we systematically designed and synthesized a series of 2-substituted aniline pyrimidine derivatives as potent MerTK inhibitors. The lead compound 15f demonstrated excellent inhibitory activity against Mer kinase with an IC50 value of 37.5 ± 2.7 nM, coupled with broad-spectrum antiproliferative activities against A2780, MDA-MB-231, and HCT116 cancer cell lines. Notably, 15f exhibited minimal hERG liability, addressing critical safety concerns. Mechanistic studies revealed dose-dependent inhibition of cancer cell migration and induction of apoptosis, while pharmacokinetic evaluation demonstrated favorable drug-like properties including high AUC, prolonged half-life, and good oral bioavailability (F: 32.4 %). The bioavailability of 15f was significantly higher than that of compound UNC2250 (F: 23 %). These integrated findings position 15f as a structurally novel and multi-faceted MerTK inhibitor for therapeutic application in cancer patients.